News for Healthier Living

Moffitt Researchers Show That Reactivity to Tumor Antigens is Important for TIL Therapy

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published in Nature Cancer, may help improve future ways to deliver this cellular immunotherapy for metastatic non-small cell lung cancer.

May 8, 2025


May 15 2025

May 14 2025

May 13 2025

May 12 2025

May 11 2025

May 10 2025

May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025